TRANSCATHETER TECHNOLOGIES GmbH closes a Euro 1.7 million ‘Series A’ financing round

TRANSCATHETER TECHNOLOGIES GmbH, a transcatheter heart valve company that is developing TRINITY a fully repositionable device for transcatheter aortic valve implantation, announced today that it has closed a Euro 1.7 million ‘Series A’ financing round.

Existing investors Technologie-Seed-Beteiligungsfonds Bayern GmbH & Co. KG and High-Tech Gründerfonds GmbH also participated in this funding round. New investors are Tubaflex Beteiligungs GmbH, Kreditanstalt für Wiederaufbau (KFW), ERP-Startfonds, Clusterfonds EFRE Bayern and other private investors. The round was led by Dr. Rolf Kaese, former CEO of both Berlin Heart GmbH and Impella CardioSystems AG. The funding will be used to technically validate the TRINITY technology.

Dr. Kaese from Tubaflex and Dirk Dreyer, Director Globals Sales & Marketing and member of the Executive Board of Straub Medical AG, Switzerland will join Transcatheter Technologies GmbH advisory board.

“We are thrilled to be joined by Dr. Rolf Käse and Dirk Dreyer on the advisory board. Their extensive experience in the medical device industry is invaluable.” said Dr. Wolfgang Goetz, CEO and cardiac surgeon. “The new investment round will allow Transcatheter Technologies GmbH to take the next steps necessary towards the initial first in-human implantation. In order to make implantations much safer our innovative TRINITY-System is fully repositionable. In addition, the new valve design serves to improve the durability of the prosthesis. Compared to other systems TRINITY is expected to make transcatheter heart valve implantations available to a wider range of patients.”

About TRANSCATHETER TECHNOLOGIES GmbH
TRANSCATHETER TECHNOLOGIES GmbH, incorporated in 2009, is a privately held company located in Regensburg, Germany. It is currently developing TRINITY, a proprietary system for transcatheter aortic valve implantation. The TRINITY transcatheter aortic heart valve prosthesis and implantation system combine a novel anchoring mechanism with a unique delivery catheter to enable the valve prosthesis to be accurately and precisely positioned. TRINITY can be repeatedly deployed and repositioned without foreshortening of the valve prosthesis frame. The TRINITY valve is pre-mounted on a detachable tip to simplify the assembly of the catheter system in the operating room and remove the risk of misalignment.

Contact:
Transcatheter Technologies GmbH
Wolfgang Goetz
MD, PhD, CEO
BioPark Regensburg
Josef-Engert-Str. 11
93053 Regensburg
Germany
Tel: +49 170 6309920
wolfgang.goetz@transcatheter-technologies.com
www.transcatheter-technologies.com

About High Tech Gründerfonds
High-Tech Gründerfonds invests venture capital in young, high-opportunity technological companies implementing promising research results in an entrepreneurial manner. The start-up companies are planned to lead their R&D projects to the production of a prototype or a “proof of concepts” or market launch by means of the seed financing of up to 500k EUR. The High-Tech Gründerfonds has a fund volume of around 272m EUR. Investors of the public-private partnership are the Federal Ministry for Economics and Technology, the KfW bank group as well as the six industrial groups BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss.

Contact:
High-Tech Gruenderfonds Management GmbH
Michael Nettersheim
Senior Investment Manager
Ludwig-Erhard-Allee 2
53175 Bonn
Tel: +49 228 823001-00
Fax: +49 228 823000-50
m.nettersheim@high-tech-gruenderfonds.de
www.high-tech-gruenderfonds.de